Literature DB >> 3872638

Reduced opsonisation of protein A containing Staphylococcus aureus in sera with cryoglobulins from patients with active systemic lupus erythematosus.

O Nived, C Linder, H Odeberg, B Svensson.   

Abstract

Among a total of 41 patients with systemic lupus erythematosus (SLE) 11 of 14 patients with active disease had reduced capacity (p less than 0.05) to opsonify Staphylococcus aureus in undiluted sera, as compared with nine of 27 patients with inactive disease (p less than 0.02). The opsonic reduction in the active patients increased with the number of active organ systems (p less than 0.002). No correlation was found between reduced opsonisation and corticosteroid treatment, or serum concentrations of complement components (C) of the classical pathway, or bacteria-associated activated C3. When the cryoglobulin fraction of immune complexes (IC) was removed, normal opsonic capacity was restored, and the opsonic reduction could be transferred with the cryoglobulins to pooled serum. Increased IC values, as measured by C1q binding assay, were found in conjunction with reduced opsonic capacity (p less than 0.04). Since opsonisation in SLE sera of a protein A deficient strain of S. aureus was normal, reduced S. aureus phagocytosis in SLE sera may be explained by IC binding to staphylococcal protein A.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3872638      PMCID: PMC1001621          DOI: 10.1136/ard.44.4.252

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  31 in total

1.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

2.  Infections due to neutrophil malfunction.

Authors:  P G Quie
Journal:  Medicine (Baltimore)       Date:  1973-09       Impact factor: 1.889

3.  Kinetics of staphylococcal opsonization, attachment, ingestion and killing by human polymorphonuclear leukocytes: a quantitative assay using [3H]thymidine labeled bacteria.

Authors:  J Verhoef; P K Peterson; P G Quie
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

4.  Staphylococcal protein A fluoroimmunoassay for immune complexes.

Authors:  I Faiferman; D Koffler
Journal:  Arthritis Rheum       Date:  1982-07

5.  Effects of cryoglobulins and aggregated IGG on in vitro monocyte phagocytosis.

Authors:  B Svensson; R Norberg; R Torstensson
Journal:  Scand J Rheumatol Suppl       Date:  1980

6.  Properdin deficiency in a family with fulminant meningococcal infections.

Authors:  A G Sjöholm; J H Braconier; C Söderström
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

7.  Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus.

Authors:  R H Zubler; G Lange; P H Lambert; P A Miescher
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

8.  Detection of circulating IgG aggregates and immune complexes using 125I protein A from Staphylococcus aureus.

Authors:  R Hällgren; L Wide
Journal:  Ann Rheum Dis       Date:  1976-08       Impact factor: 19.103

9.  Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE).

Authors:  W Lloyd; P H Schur
Journal:  Medicine (Baltimore)       Date:  1981-05       Impact factor: 1.889

10.  Monocyte in vitro function in systemic lupus erythematosus (SLE). I. A clinical and immunological study.

Authors:  B Svensson
Journal:  Scand J Rheumatol Suppl       Date:  1980
View more
  2 in total

1.  Overwhelming pneumococcal bacteraemia in systemic lupus erythematosus.

Authors:  D Petros; S West
Journal:  Ann Rheum Dis       Date:  1989-04       Impact factor: 19.103

2.  Antimalarial treatment and minimizing prednisolone are associated with lower risk of infection in SLE: a 24-month prospective cohort study.

Authors:  Ana Rita Prata; Mariana Luís; Helena Assunção; José António Pereira da Silva; Luís Sousa Inês
Journal:  Clin Rheumatol       Date:  2021-11-16       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.